Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) SEC filings page provides access to the company’s regulatory disclosures as a public issuer. These documents include current reports on Form 8-K, periodic reports and other filings that describe clinical progress, material agreements, capital raises, governance changes and stockholder actions.
For investors tracking 4D Molecular Therapeutics’ gene therapy programs, Form 8-K filings are particularly relevant. Recent 8-Ks have covered topics such as interim clinical data from the PRISM Phase 1/2 trial of 4D-150 in wet age-related macular degeneration, updates on the AEROW trial of 4D-710 in cystic fibrosis lung disease, the collaboration and license agreement with Otsuka Pharmaceutical for 4D-150 in Asia-Pacific markets, and the appointment or transition of key executives and directors. Other 8-Ks report on equity offerings, preliminary cash and investment balances, and amendments to corporate bylaws.
Filings also disclose that 4D Molecular Therapeutics’ common stock trades on the Nasdaq Global Select Market under the symbol FDMT, and they provide details on matters submitted to stockholder votes, such as director elections, auditor ratification and advisory votes on executive compensation and its frequency.
On Stock Titan, these SEC filings are updated in near real time from the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key terms of collaboration and license agreements, explain the implications of financing transactions, and surface important information about clinical data disclosures, governance changes and cash runway guidance. Users can also review filings that relate to equity offerings, including underwriting agreements and pre-funded warrants, and examine how these transactions fit into 4D Molecular Therapeutics’ overall development and funding strategy.
4D Molecular Therapeutics reported that affiliates of The Goldman Sachs Group, Inc., including Goldman Sachs & Co. LLC, beneficially owned 4,286,077.48 shares of its common stock as of 12/31/2025. This represents 7.5% of the company’s outstanding common shares.
The Goldman Sachs entities report shared voting power over 4,286,060.48 shares and shared dispositive power over 4,286,077.48 shares, with no sole voting or dispositive power. They state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of 4D Molecular Therapeutics.
4D Molecular Therapeutics entered exchange agreements with RA Capital and Biotechnology Value Fund, under which RA Capital exchanged 4,850,000 common shares and BVF exchanged 1,750,000 common shares for pre-funded warrants to acquire the same number of shares.
As of January 23, 2026, the company had 51,007,874 common shares outstanding, excluding 16,935,665 shares issuable upon exercise of pre-funded warrants outstanding on that date. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share, have no expiration until fully exercised, and are subject to beneficial ownership blockers at 4.99% or 9.99%, as specified in each warrant. The warrants were issued without registration in reliance on the Section 3(a)(9) exemption under the Securities Act.
4D Molecular Therapeutics director Glenn Sblendorio reported a grant of stock options in the company. On January 5, 2026, he received 45,000 stock options to buy common shares at an exercise price of $7.30 per share. These options expire on January 4, 2036.
One-third of the options vest on the first anniversary of January 5, 2026, and the remaining two-thirds vest in equal monthly installments over the following two years. After this grant, Sblendorio beneficially owned 45,000 derivative securities directly.
4D Molecular Therapeutics director Glenn Sblendorio reported initial beneficial ownership of a stock option covering 11,250 shares of the company’s common stock at an exercise price of $2.76 per share. The option was granted on April 9, 2025 and vests over three years: one-third of the shares vest on the first anniversary of that date, with the remaining two-thirds vesting in equal monthly installments over the following two years, so that all 11,250 shares are fully vested and exercisable on the third anniversary.
4D Molecular Therapeutics reported a preliminary estimate of approximately $514 million in cash, cash equivalents and marketable securities as of December 31, 2025, noting this figure is unaudited and may change once year-end closing procedures are complete. The company also announced that President and Chief Operating Officer Fariborz Kamal, Ph.D., resigned from those roles on December 31, 2025 to pursue other opportunities, and moved to a part-time position as Chief Technical Advisor, with no disagreements cited regarding operations or strategy.
Effective January 1, 2026, Chief Executive Officer David Kirn, M.D., was also appointed President. In addition, effective January 5, 2026, the Board appointed Glenn Sblendorio as a Class I director and member of the Compensation and Science and Technology Committees, granting him an initial option to purchase 45,000 shares at an exercise price of $7.30 per share and cash retainers consistent with the company’s non-employee director compensation program.
4D Molecular Therapeutics director Charles Theuer reported exercising a stock option for 9,333 shares of common stock at $1.14 per share on December 12, 2025. The transaction is shown as an acquisition of common stock following the exercise of a fully vested stock option originally granting the right to buy 9,333 shares at $1.14, with an expiration date of March 9, 2026. After this transaction, Theuer directly beneficially owned 41,684 shares of 4D Molecular Therapeutics common stock and held no remaining derivative securities from this option grant.
4D Molecular Therapeutics, Inc. reported an equity award for its Chief Financial Officer. The officer received a stock option covering 480,000 shares of common stock at an exercise price of $10.51 per share, dated 12/09/2025, with the option expiring on 12/08/2035.
According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of the November 17, 2025 vesting commencement date. The remaining shares vest in 36 equal monthly installments so that the option is fully vested on the fourth anniversary of that date, provided the officer continues as a service provider to the company.
4D Molecular Therapeutics, Inc. reported that its Chief Financial Officer, Kristian Humer, had no beneficial ownership of the company’s securities as of December 9, 2025. The Section 16(a) insider ownership report indicates that no non-derivative or derivative securities of 4D Molecular Therapeutics are beneficially owned, and the filing was made for one reporting person.
4D Molecular Therapeutics, Inc. (FDMT)1,635 shares of common stock at $4.14 per share and, on the same date, sold 1,635 shares at $10.59 per share under a Rule 10b5-1 trading plan adopted on June 6, 2025. After these trades, the officer directly holds 3,594 shares of common stock and 75,230 stock options. The option underlying this transaction covers 1,635 shares and vests in equal monthly installments over four years starting from March 6, 2025, as long as the officer continues to serve the company.
4D Molecular Therapeutics, Inc. (FDMT) appointed Kristian Humer as its new Chief Financial Officer and Principal Financial Officer effective November 17, 2025. Humer brings experience from senior finance roles at Foghorn Therapeutics, Viridian Therapeutics, and Citigroup’s healthcare investment banking group. Under his offer letter, he receives an annual base salary of $520,000, a target annual bonus equal to 40% of base salary, a stock option to purchase 480,000 shares of common stock, and a $100,000 sign-on bonus paid in two installments with multi-year earn-out conditions tied to continued employment. If he is terminated without cause or resigns for good reason, he is eligible for severance benefits, including salary continuation and COBRA premium reimbursement, with enhanced benefits and full vesting acceleration of equity awards if such a termination occurs within 12 months after a change in control.
FAQ
What is the current stock price of 4D Molecular Therapeutics (FDMT)?
What is the market cap of 4D Molecular Therapeutics (FDMT)?
